4//SEC Filing
Bruhn Suzanne Louise 4
Accession 0000950170-24-054699
CIK 0001827087other
Filed
May 6, 8:00 PM ET
Accepted
May 7, 5:00 PM ET
Size
17.6 KB
Accession
0000950170-24-054699
Insider Transaction Report
Form 4
Bruhn Suzanne Louise
Director
Transactions
- Disposition to Issuer
Stock Option Award (Right to Buy)
2024-05-03$7.62/sh−6,235$47,498→ 0 totalExercise: $11.87Exp: 2033-03-01→ Common Stock (6,235 underlying) - Award
Stock Option Award (Right to Buy)
2024-05-03+13,928→ 13,928 totalExercise: $3.03Exp: 2033-06-07→ Common Stock (13,928 underlying) - Disposition to Issuer
Stock Option Award (Right to Buy)
2024-05-03−13,928→ 0 totalExercise: $10.00Exp: 2033-06-07→ Common Stock (13,928 underlying) - Disposition to Issuer
Stock Option Award (Right to Buy)
2024-05-03−24,310→ 0 totalExercise: $6.93Exp: 2032-07-27→ Common Stock (24,310 underlying) - Award
Stock Option Award (Right to Buy)
2024-05-03+24,310→ 24,310 totalExercise: $3.03Exp: 2032-07-27→ Common Stock (24,310 underlying) - Award
Stock Option Award (Right to Buy)
2024-05-03+6,235→ 6,235 totalExercise: $3.03Exp: 2033-03-01→ Common Stock (6,235 underlying)
Footnotes (5)
- [F1]On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment having vested on August 27, 2022.
- [F3]The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability.
- [F4]This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this stock option award are fully vested and exercisable as of the date hereof.
- [F5]This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders.
Documents
Issuer
Vigil Neuroscience, Inc.
CIK 0001827087
Entity typeother
Related Parties
1- filerCIK 0001517790
Filing Metadata
- Form type
- 4
- Filed
- May 6, 8:00 PM ET
- Accepted
- May 7, 5:00 PM ET
- Size
- 17.6 KB